Aelis Farma SA (EPA:AELIS)

France flag France · Delayed Price · Currency is EUR
1.278
+0.008 (0.63%)
Apr 28, 2026, 5:18 PM CET
4.33%
Market Cap 17.37M
Revenue (ttm) 2.33M
Net Income (ttm) -8.20M
Shares Out 13.59M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,854
Average Volume 26,625
Open 1.304
Previous Close 1.270
Day's Range 1.216 - 1.304
52-Week Range 0.672 - 2.300
Beta 0.60
RSI 47.35
Earnings Date Mar 30, 2026

About Aelis Farma

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase II clinical trials to treat cognitive deficits observed in down syndrome, as well as other cognitive imp... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 24
Stock Exchange Euronext Paris
Ticker Symbol AELIS
Full Company Profile

Financial Performance

In 2024, Aelis Farma's revenue was 5.56 million, a decrease of -54.99% compared to the previous year's 12.36 million. Losses were -7.46 million, 46.8% more than in 2023.

Financial Statements

News

There is no news available yet.